Sofosbuvir (Sovaldi) for the treatment of hepatitis C. (Q38219424)

31 August 2017

title

Sofosbuvir (Sovaldi) for the treatment of hepatitis C. (English)

1 reference

31 August 2017

0 references

Brian Lam

1

1 reference

31 August 2017

Linda Henry

series ordinal

2

1 reference

31 August 2017

Zobair Younossi

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

11 June 2014

1 reference

Expert Review of Clinical Pharmacology

31 August 2017

published in

1 reference

31 August 2017

volume

7

1 reference

31 August 2017

issue

5

1 reference

31 August 2017

page(s)

555-566

1 reference

Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Hepatitis C virus infection in USA: an estimate of true prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

The natural history of hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Chronic hepatitis C virus (HCV) disease burden and cost in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.928196

10.1586/17512433.2014.928196

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference